Reactive Oxygen Species‐Responsive Polymeric Prodrug Nanoparticles for Selective and Effective Treatment of Inflammatory Diseases
Advanced Healthcare Materials · 2023-11 · 12 (29)
DOI: 10.1002/adhm.202301394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.08.2023. Verfasst von Yaming Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology & Dr. Li Dak-Sum Research Centre & Department of Pharmacology and Pharmacy, Li Ka Shing Faculty …. Hauptthemen laut MEDLINE: Prodrugs, Nanoparticles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Li Dak-Sum Research Centre, The University of Hong Kong, Li Ka Shing Faculty of Medicine, The University of Hong Kong, National Natural Science Foundation of China.
Abstract (Originalsprache)
It is challenging to manage inflammatory diseases using traditional anti‐inflammatory drugs due to their limited efficacy and systemic side effects, which are a result of their lack of selectivity, poor stability, and low solubility. Herein, it reports the development of a novel nanoparticle system, called ROS‐CA‐NPs, which is formed using polymer‐cinnamaldehyde (CA) conjugates and is responsive to reactive oxygen species (ROS). ROS‐CA‐NPs exhibit excellent drug stability, tissue selectivity, and controlled drug release upon oxidative stress activation. Using mouse models of chronic rheumatoid arthritis and acute ulcerative colitis, this study demonstrates that the systemic administration of ROS‐CA‐NPs results in their accumulation at inflamed lesions and leads to greater therapeutic efficacy compared to traditional drugs. Furthermore, ROS‐CA‐NPs present excellent biocompatibility. The findings suggest that ROS‐CA‐NPs have the potential to be developed as safe and effective nanotherapeutic agents for a broad range of inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology & Dr. Li Dak-Sum Research Centre & Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Respiratory Disease, School of Biomedical Engineering & The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260,…
- College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, 325027, China.
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Zhongyu Li, Weiping Wang
Förderung
- Dr. Li Dak-Sum Research Centre, The University of Hong Kong
- Li Ka Shing Faculty of Medicine, The University of Hong Kong
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province of China
Zitieren
APA
Zhang, Y., Liu, L., Wang, T., Mao, C., Shan, P., Lau, C. S., Li, Z., Guo, W., & Wang, W. (2023). Reactive Oxygen Species‐Responsive Polymeric Prodrug Nanoparticles for Selective and Effective Treatment of Inflammatory Diseases. Advanced Healthcare Materials, 12(29). https://doi.org/10.1002/adhm.202301394
Vancouver
Zhang Y, Liu L, Wang T, Mao C, Shan P, Lau CS, et al. Reactive Oxygen Species‐Responsive Polymeric Prodrug Nanoparticles for Selective and Effective Treatment of Inflammatory Diseases. Advanced Healthcare Materials. 2023;12(29). doi:10.1002/adhm.202301394
BibTeX
@article{Zhang2023,
author = {Zhang, Yaming and Liu, Lu and Wang, Tianyi and Mao, Cong and Shan, Pengfei and Lau, Chak Sing and Li, Zhongyu and Guo, Weisheng and Wang, Weiping},
title = {Reactive Oxygen Species‐Responsive Polymeric Prodrug Nanoparticles for Selective and Effective Treatment of Inflammatory Diseases},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {29},
doi = {10.1002/adhm.202301394}
}
EUVIMED